The variable domain resurfacing and CDR-grafting approaches to antibody humanization were compared directly on the two murine monoclonal antibodies N901 (anti-CD56) and anti-B4 (anti-CD19). Resurfacing replaces the set of surface residues of a rodent variable region with a human set of surface residues. The method of CDRgrafting conceptually consists of transferring the CDRs from a rodent antibody onto the Fv framework of a human antibody. Computer-aided molecular modeling was used to design the initial CDR-grafted and resurfaced versions of these two antibodies. The initial versions of resurfaced N901 and resurfaced anti-B4 maintained the full binding affinity of the original murine parent antibodies and further refinements to these versions described herein generated five new resurfaced antibodies that contain fewer murine residues at surface positions, four of which also have the full parental binding affinity. A mutational study of three surface positions within 5 A of the CDRs of resurfaced anti-B4 revealed a remarkable ability of the resurfaced antibodies to maintain binding affinity despite dramatic changes of charges near their antigen recognition surfaces, suggesting that the resurfacing approach can be used with a high degree of confidence to design humanized antibodies that maintain the full parental binding affinity. By comparison CDR-grafted anti-B4 antibodies with parental affinity were produced only after seventeen versions were attempted using two different strategies for selecting the human acceptor frameworks. For both the CDR-grafted anti-B4 and N901 antibodies, full restoration of antigen binding affinity was achieved when the most identical human acceptor frameworks were selected. The CDR-grafted anti-B4 antibodies that maintained high affinity binding for CD19 had more murine residues at surface positions than any of the three versions of the resurfaced anti-B4 antibody. This observation suggests that the resurfacing approach can be used to produce humanized antibodies with reduced antigenic potential relative to their corresponding CDRgrafted versions.
Introduction
The method of immunoglobulin variable domain resurfacing (Pedersen et al., 1994; Roguska et al, 1994) attempts to reduce the immunogenicity of murine antibodies while maintaining their affinity and specificity by humanizing only the surface accessible residues located at conserved positions of the Fv framework. Differences in the presentation of surface residues in a small number of murine and human antibody variable regions have been described by Padlan (1991) , and a statistical analysis of a large database of murine and human immunoglobulin sequences revealed that the variable domains of murine and human antibodies have distinct sets of surface residues that mirror the V-gene families (Kabat et al., 1991; Pedersen et al., 1994) . No mouse framework displays the exact pattern of surface residues found in any human framework, but generally only a small number of changes are required to convert the set of surface residues in a murine Fv to that of the most identical surface pattern found on a human Fv. Thus, a general algorithm for the humanization of murine Fvs by variable domain resurfacing was developed and successfully applied to two murine monoclonal antibodies, N901 and anti-B4 (Pedersen et al., 1994; Roguska et al., 1994) .
In its simplest form, the method of CDR-grafting for humanizing antibodies consists of grafting the CDRs from a rodent antibody onto the Fv frameworks of a human antibody. Constructs made in this way have the advantage of containing a minimal number of murine residues in the variable region. However the successful design of high-affinity CDR-grafted antibodies usually requires that key murine residues be substituted into the human acceptor framework to preserve the CDR conformations (reviewed in Winter and Harris, 1993) . Although progress has been made towards identifying such framework residues either experimentally (Foote and Winter, 1992) or by computational methods (Queen et al., 1989) , this process is generally unique for each reshaped antibody and can therefore be difficult to predict (Kolbinger et al., 1993) . For many CDRgrafted antibodies, the percentages of murine residues in the human framework may not differ significantly from those found for corresponding resurfaced versions.
The resurfacing algorithm as previously described preserved murine residues at surface positions if they were located within 5 A of a CDR in order to maintain CDR conformations. A mutational analysis of the surface positions within 5 A of the CDRs of the resurfaced antibodies N901 and anti-B4 has now led to resurfaced antibodies containing fewer murine surface residues. These versions are compared with the corresponding CDR-grafted N901 and anti-B4 antibodies and with the published sequences of other CDR-grafted antibodies. Kabat (Kabat et al., 1991) is included for comparison.
et al., 1983) , and the CD56 antigen found on human natural killer cells (IgGl, K; Griffin et al., 1983; Nitta et al, 1989) , respectively. The human cell lines, SW-2, developed by Smith et al., (1989) , and the human lymphoblastoid line, Namalwa, (A.T.C.C. CRL 1432) were used as the CD56-positive and CD19-positive cell lines, respectively.
Molecular modeling
Models of the murine and humanized Fvs were generated as described previously using the methods of Martin et al. (1989 Martin et al. ( , 1991 and recent modifications (Pedersen et al., 1992; Rees et al., 1995) , which are encoded in the program AbM (Oxford Molecular Group, UK). The structures of the most identical sequences in the database of crystal structures were used to model the light and heavy chain variable regions. The V H and V L domains were paired by a least-squares fit onto the most structurally conserved strands of the Fv P-barrel, and then the framework side chains were introduced using a maximum overlap procedure. CDR backbone conformations were constructed using canonical loop structures where possible (Chothia and Lesk, 1987; Chothia et al., 1989) , otherwise they were built using the CAMAL algorithm (Martin et al., 1989 (Martin et al., , 1991 Pedersen et al., 1992) , which combines a C a search of the Brookhaven Protein Databank with an ab initio conformational search, followed by a series of screening steps. Framework residues in the murine and humanized anti-B4 and N901 models were then examined by a 5 A proximity procedure . This method analyzes framework CDR interactions that have the potential to contribute to antigen binding. If a framework residue was located within 5 A of a CDR and there was a change in size, charge, hydrophobicity, or potential to form hydrogen bonds that could disturb a CDR conformation, the human residue was considered a candidate for replacement by the amino acid from the murine Fv.
Construction of humanized V-region genes
The resurfaced and CDR-grafted V H and V L genes were constructed by extension and amplification of four overlapping oligonucleotides (120-130 nucleotides) comprising alternating 896 strands of the full-length genes (Daugherty et al., 1991) . For N901, the assembled V H and V L genes encoded the following sequences in order (5'-3'): a HindWl cloning site, the consensus Kozak sequence (5'-GCCGCCACC-3') (Kozak, 1989) , an immunoglobulin signal sequence (Jones et al., 1986) , an intron, the humanized V H or V L coding region, a 3' non-coding sequence including a splice site, and a BamHl cloning site. For anti-B4, the assembled V H and V L genes differ from the above only by the elimination of an intron between the immunoglobulin signal sequence and the V H or V L coding region. The assembled humanized variable-region genes were subcloned into immunoglobulin expression vectors derived from HCMV-V L Lys-K R (Maeda et al., 1991) , containing either the human constant K exon or human-yl constant region gene. Expression vectors carrying the resurfaced and CDR-grafted anti-B4 variable-region genes differ from the N901 expression vectors by the addition of the human DHFR cDNA positioned at the 5' end of the cytomegalovirus (CMV) enhancer in reverse orientation with respect to the CMV promoter. Mutant V H and V L variable-region genes were constructed by PCR mutagenesis (Ho et al., 1989) or by site-directed mutagenesis according to Kunkel et al. (1987) of the CDR-grafted and resurfaced frameworks.
Expression and purification of recombinant antibodies
Three days prior to transfection, COS cells were plated on 15 cm tissue culture dishes at 2X10 6 cells/30 ml/plate in DMEM supplemented with 10% bovine calf serum (total of 12 plates per experiment) which were incubated at 37°C in 7% CO2. After 3 days, each dish was washed twice with 10 ml HBS (137 mM NaCl, 5 mM KC1,0.7 mM Na 2 HPO 4 , 6 mM dextrose, 20 mM HEPES, pH 7.05), and then treated with 5 ml trypsin solution (Gibco) for 5 min at 37°C, followed by vigorous pipetting to detach and disaggregate the cells. The cell suspension was then added to 5 ml SFM (Hybridoma Serum Free Medium, Gibco). Cells were pelleted by centrifugation for 5 min at 300 g and supernatants removed by aspiration. Cell pellets (each about 1X10 7 cells) were washed twice in 10 ml HBS, resuspended in 0.8 ml HBS containing 40 \ig each of the V H and V L immunoglobulin expression plasmids, and then transferred to 0.4 cm electroporation cuvettes. Cuvettes containing the mixture of COS cells and expression plasmids were chilled on ice for 10 min, and then pulsed at 230 V and 960 (J.F in a Bio-Rad electroporation apparatus, followed by incubation on ice for 10 min. Following electroporation, cells from individual cuvettes were added to 40 ml of SFM, plated in a 15 cm tissue culture dish, and incubated at 37°C in 7% CO 2 . The supernatant was harvested from the transfected cells 3 days after transfection. Pooled cell supernatants (approximately 450 ml total) were centrifuged for 20 min at 4500 g, filtered through a 0.22 (im filter and concentrated to a final volume of 30 ml using a stirred cell apparatus fitted with an Amicon YM10 membrane. Tris-HCl (pH 7.4) was added to a final concentration of 0.1 M and the resulting solution was applied to a column of immobilized protein A (Pierce Chemical Co., Rockford, IL.). The column was washed with 0.1 M Tris-HCl buffer, pH 7.4, containing 0.15 M NaCl. The bound antibody was eluted with 100 mM acetic acid containing 150 mM NaCl, and then dialyzed against 10 mM sodium phosphate, 150 mM NaCl, pH 7.4. Protein concentration was determined by measuring absorbance at 280 nm and assuming £' % i cm of 14.0 for IgG. Yields of antibodies were typically 1-2 mg from 0.5 1 of cell culture supernatant. Antibodies produced in this manner are free from any contaminating bovine immunoglobulin as determined by isoelectric focusing gels , thus allowing accurate concentration measurements. The purity and integrity of the purified products were confirmed by polyacrylamide gel electrophoresis under reducing and nonreducing conditions. To prevent any non-specific losses due to adsorption, bovine serum albumin at a final concentration of 1 mg/ml was added to the purified antibody for storage prior to binding studies.
Competition binding assay
Competition binding assays were performed as described previously (Lambert et al., 1991) . Briefly, Namalwa cells (CD19 antigen-positive, 3X10 5 cells/well) or SW2 cells (CD56 antigen-positive, 5X 10 5 cells /well) in AB buffer [2.5% pooled human AB serum (Whittaker) in minimal essential medium (Whittaker)] were plated at 25 |il per well in 96-well dishes. Twenty-five microliters of AB buffer containing fiuoresceinlabeled anti-B4 (4-6 nM) or N901 (1-3 nM) antibody mixed with various concentrations of competing murine or recombinant antibody were added to each well. Positive controls lacked competing antibody while negative controls lacked fiuoresceinlabeled anti-B4 or N901. Plates were incubated for 30 min at 4°C. The cells were washed once with AB buffer (175 \l\J well) and fixed with 1% formaldehyde in 10 mM potassium phosphate, 150 mM NaCl, pH 7.2. The labeled cells were analyzed on a FACScan flow cytometer (Becton-Dickinson) set on linear fluorescence. The binding of fluorescently-labeled antibody was expressed as a percentage of the fluorescence of the positive control.
Indirect binding assay
Namalwa cells (for anti-B4) or SW2 cells (for N901) were mixed with carrier 4.5 u.m polystyrene microspheres (Polysciences, Inc.) and washed twice in 10 ml NGS buffer (2.5% goat serum, 2 mM HEPES, pH 7.2, in minimal essential medium) at 4°C and resuspended in NGS buffer at 2X1O 5 cells/ml. Cells (2X1 Orwell) and microspheres (1.8X 10 6 /well) were plated at 100 |il/well in 96-well dishes. Various concentrations of primary murine or recombinant human IgG, antibodies were added to each well in 100 (J.1 of NGS buffer. One hundred microlitres of NGS buffer lacking primary antibody were added to control wells. The plates were incubated at 4°C for 2 h, and then washed twice with 200 u.1 NGS buffer. Fiuorescein-labeled secondary antibodies (goat anti-human or goat anti-mouse) were added in 100 JJ. 1 NGS buffer per well and plates were incubated in the dark for 1 h at 4°C. The cells were again washed twice with NGS buffer (200 (j.1), fixed with 1% formaldehyde in 10 mM potassium phosphate, 150 mM NaCl, pH 7.2, and analyzed on a FACScan flow cytometer (Becton-Dickinson). The binding of antibody to cells is expressed as the fraction of maximal fluorescence.
Results

Humanization of murine monoclonal antibody N90J by CDR grafting
The human frameworks chosen to accept the N901 CDRs, KV2F V L (Klobeck et al., 1985) and G360O5 V H (Schroeder et al., 1990) , were selected based on their highest sequence identity to the N901 V L and V H framework sequences ( Figure 1 ). The V L amino acids of N901 and K.V2F were the same at 66 of 80 (84%) framework positions, and the V H amino acids of N901 and G36OO5 were identical at 80 of 94 (86%) framework positions. Modeling identified the two human Fv residues Val3 and Arg52 as falling within 5 A of a CDR and having the potential to disturb CDR conformation. Val3 is adjacent to Arg24 and could alter the structure of CDR LI. Arg52 is located between Glu40 in CDR LI and Met228 in CDR H3 and could influence the conformation of either CDR. Therefore, both of these residues were replaced with Leu, the corresponding residue at both positions in the murine N901 V L . A third residue in the human V L , Gin 108, had the potential of interfering 
with the docking of the KV2F V L and G36OO5 V H , and was replaced with the murine Gly. A CDR grafted N901 antibody incorporating these substitutions (GN9Olv7.0, Table  1A ) was made and its binding to SW-2 cells was assessed by an indirect immunofluorescence assay and a competition binding assay. In both assays, the binding of the CDRgrafted GN9Olv7.0 antibody was indistinguishable from that of the parent murine N901 antibody (Figure 2A,C) .
In order to minimize the antigenic potential of the CDR grafted N901 antibody, we wished to test whether it was possible to reduce the overall occurrence of murine residues in the human frameworks while maintaining the binding affinity of the murine antibody. Although the assumption made in our analysis is that there may be interactions between residues that are predicted by modeling to be within 5 A of one another, the influence of such interactions between CDR and framework residues on antigen binding is difficult to predict and must be experimentally determined (Glaser et al, 1992; Wilson and Stanfield, 1993) . Therefore, antibody version GN9Olv7.7 was constructed, which restored the original human residues Val, Arg, and Gin at the three framework positions 3, 52, and 108. GN901v7.7 thus contained no murine residues in the human frameworks. When this antibody was analyzed for binding on SW-2 cells, it was also found to be indistinguishable from that of the parent murine N901 antibody ( Figure 2B,C) . Thus, N901 is a rare example of a murine antibody that was humanized by simply transferring its CDRs onto the most identical human variable-region frameworks while retaining the binding affinity of the original murine monoclonal antibody. This is likely a consequence of the high sequence identity between the murine and human framework sequences.
Humanization of murine monoclonal antibody anti-B4 by CDR grafting Selection of most identical native human Fv.
In designing the CDR-grafted anti-B4 antibody, two methods for selecting the human acceptor frameworks were considered. For a design 898 based on using the most identical human V H and V L frameworks, the strategy that had been applied successfully for the CDR grafting of the N901 antibody, the most identical human frameworks found in the database (Figure 1) were the human V H 21/28 (Dersimonian et al., 1987) and human V L POP (Spatz et al., 1990) . For an alternative design based on using the most identical clonally derived VH-V L pair, the strategy used successfully for the resurfacing of anti-B4, the most identical human Fv was LS5 (Silberstein et al, 1989) . The advantage of the latter strategy is that it ensures proper association of the V H and V L subunits without the need for evaluation by molecular modeling of the quality of VJ^-VL docking, and that it reduces the risk of generating potentially immunogenic neoepitopes that might be presented by the pairing of non-native heavy and light chains. While the advantage of the former strategy is that V H and V L sequences of higher homology to the murine sequences can be selected, the overall framework homologies of the two human sequences with respect to anti-B4 were quite similar. The LS5 V H and 21/28 V H were found to be 71% and 77% identical to the anti-B4 VH, and the LS5 V L and POP V L were found to be 70% and 73% identical to the anti-B4 V L , respectively (Figure 1) . Models of the murine and humanized anti-B4 Fvs were constructed and analysed by the 5 A proximity procedure as described. Six LS5 human framework residues that had the potential to alter a CDR conformation were identified and replaced with the corresponding murine residue from the parent anti-B4 (Table IIA) . This version, GB4v7.£>, was made and analysed for binding to antigen-positive Namalwa cells ( Figure  3A,D) . In two different assays, binding affinity was reduced by about a factor of 10 relative to the parent murine anti-B4. In an attempt to improve the binding of GB4v7.0, nine subsequent antibodies were derived from GB4v7.0 by substituting the appropriate murine residues at different LS5 framework positions (Table IIA, constructed by introducing murine residues at V H positions 182, 184, and 185. These residues are included in CDR H2 according to Kabat et al. (1991) , although in our approach they are modeled as framework residues (Pedersen et al., 1994; Roguska et al, 1994) . While little evidence exists for the direct interaction of residues in this region with antigens, the amino acids positions 182, 184, and 185 are highly conserved, which suggested that they might serve a CDRscaffold function. However, even though the binding affinity of GB4v7.7 was increased relative to GB4v7.0, it was still less than that of the murine anti-B4. Further attempts to improve the affinity of the CDR-grafted anti-B4 by further substitutions of murine residues in the LS5 frameworks were unsuccessful (Table IIA) .
Selection of most identical human V H and V L frameworks.
In this strategy, the most identical human V H , 21/28, and most identical human V L , POP, were selected as frameworks to accept the anti-B4 CDRs. An Fv model of the anti-B4
CDRs grafted onto the 21/28 and POP frameworks was generated and potential CDR-framework interactions were identified using the 5 A proximity procedure. A CDRgrafted version GB4v2.0 was produced that contained murine residues substituted at nine human framework positions (Table IIA) . However, the binding of GB4v2.0 was similar to that of GB4v7.0, ~ 10-fold lower than that of murine anti-B4 ( Figure 3B,D) .
In an effort to improve binding affinity, the Fv models were re-examined. The 5 A proximity procedure was broadened to 6 A in an effort to identify residues which, if mutated to the corresponding murine residue, might improve the binding affinity of GB4v2.0. By this criterion, an additional six murine residues were substituted into the human frameworks (Table HA) . Two other substitutions were introduced at positions 112 and 242 based on the possible effects of these residues on the variable-constant region packing which may influence CDR conformations. Finally, Prol24 found in murine anti-B4 is a very unusual residue at this position (except for murine subgroup IIB; Kabat et al., 1991) , and proline was not found at this position in any known human antibody, leading to speculation that the unusual placement of a proline here might contribute to the binding of anti-B4. A new version was made, GB4v2J (Table IIA) , that now incorporated a total of 18 murine framework residues, and when .tested in the two binding assays it was found to be indistinguishable from the parent murine anti-B4 antibody ( Figure 3C,E) .
To further dissect the contributions of the nine additional substitutions to the binding affinity of GB4v2.7 relative to GB4v2.0, GB4v2.2 and GB4v2.5 were generated by coexpressing the light chain of GB4v2.0 and the heavy chain of GB4v2.7, and by co-expressing the light chain of GB4v2.7 with the heavy chain of GB4v2.0, respectively (Table HA) . Binding tests revealed that the binding of GB4v2.5, like GB4v2.7, was equal to that of murine anti-B4, while the binding of the GB4v2.2 version was about one-tenth of that for anti-B4 ( Figure 3C,E) . Thus, only the three additional changes in the V L framework of GB4v2.0 described above were necessary to produce the ten-fold improvement in binding affinity needed to restore the full affinity of murine anti-B4. The additional six substitutions in the 21/28 V H framework were neither necessary nor deleterious to antigen binding. The rationalization of these results will be discussed later. (Kabat et al., 1991) , but structurally it forms part of the hypervariable loop and has been shown previously to influence the binding affinity of two antibodies (Woodle et al., 1992; Presta et al., 1993) . The murine Thrl41 was introduced into GB4v/.O, GB4v/./ and GB4v/.2, creating GB4W.5, GB4v/.<5 and GB4v/.7 f Saul and Poljak (1993) found that amino acid sequence variations at V H residues 126 and 189 defined structural framework patterns in the V H region based on conformational differences in the main polypeptide chain and side-chains of residues 126, 135, 189, and 204 (AbM numbering) and suggested that these structural patterns may directly affect the conformation of some residues of CDR H2. Retention of the murine residue at position 189 was essential for maintenance of the murine binding activity in 4 variants of humanized MaEl 1 (Presta et al., 1993) . Introduction of the murine residue at this position also contributed to the successful CDR grafting of a murine anti-IgE antibody (Kolbinger et al., 1993) . GB4v/.S incorporated the murine AIal89 and Val204 into GB4v/.0. The murine Arg52 had been introduced into GB4v/.O because of potential interactions with CDR H3. The sequence of the murine anti-B4 at positions Lys51-Arg52-Trp53 is highly conserved in antibodies of the Kabat munne subgroup VI (Kabat et al., 1991) . Thus, two changes were made to GB4v/.O to generate GB4v/.9 in order to test whether the introduction of all three murine residues would restore parental binding affinity to GB4v/.O.
Contributions to binding affinity by residues located at surface positions. We wished to test whether the design of M.A.Roguska et at
the CDR-grafted anti-B4 version GB4v2.5 could be improved by applying the principles of resurfacing, which are based on the premise that the immunogenicity of a foreign protein originates with the surface residues (Pedersen et al., 1994) . The GB4v2.J human frameworks contained a total of 12 murine residues, three of which were located at solventaccessible positions, Ser76, Lysl86, and Lysl95 (Pedersen et al, 1994; Roguska et al., 1994) . We constructed and tested antibodies GB4v2.4, GB4v2.5 and GB4v2.6 (see Table   IIA ), to examine the contributions of the human Asp76 and Gin 186 either singly or in combination to the binding affinity GB4v2.3. However, the three new antibodies displayed a two-to three-fold decrease in binding relative to GB4v2.5 and murine anti-B4, indicating that the murine residues at these surface positions contribute, albeit in a small way, to maintaining the proper conformations of the CDR-grafted anti-B4 CDRs. These results are in contrast to those obtained with the resurfaced anti-B4 (see below), where the residues at these positions could be humanized with no loss of binding.
Refinement of resurfaced N901
We have previously described the modeling, construction, expression, purification, and binding characteristics of a resurfaced N901 antibody (Pedersen et al., 1994; Roguska et al., 1994) , herein called RN901v7.0 (Figure 1) . Ideally, all of the surface-exposed amino acid residues in the Fv framework of a resurfaced antibody form a human surface pattern. However, some framework surface residues of the murine antibody may be necessary to preserve the proper conformation of the CDRs or may be in direct contact with the antigen. Previously, when the RN901v7.0 Fv was modeled and compared with the model of murine Fv N901, the retention of only one murine surface amino acid was thought necessary, namely Leu at position 3 of V L . A second version of resurfaced N901, called RN901 v7.7, was constructed to test this prediction by replacing the murine Leu3 with the human Val3 ( Table I ). The apparent binding affinity of RN901v7./ for cell surface antigen was indistinguishable from that of the murine N901 in the two different binding assays ( Figure 2B,C) . Therefore the set of surface residues on the murine N901 Fv could be replaced entirely by the most identical set of human Fv surface residues without affecting the binding affinity of the antibody.
Refinement of resurfaced anti-B4
The modeling analysis of the resurfaced anti-B4 antibody described previously , herein called RB4v7.0 (Figure 1 ), had identified three residues (Ser76, Lysl86, and Lysl95) at surface framework positions that could possibly interfere with CDR conformations according to the 5' A proximity procedure. To analyze their contributions to antigen binding, they were systematically replaced with the human residues Asp76, Gin 186, and Thrl95 and the effect of these substitutions on binding affinity was determined (Table JIB, Figure 4) . The introduction of all three human residues onto the RB4v7.0 surface (version RB4v7.7J resulted in a lower binding affinity relative to RB4v7.0 and murine anti-B4 ( Figure 4A,B) . Subsequently, three versions with single mutations (RB4v7.2, RB4v7.3, and RB4v7.4J were tested, (Table IIB) . The binding affinity of each of these versions was equivalent to that of murine anti-B4 ( Figure 4A,B) . Thus, the full murine binding affinity could be maintained in the resurfaced anti-B4 by the retention of a single murine surface residue. Paradoxically, it appears that any two of the three positions can be substituted. Position 76 is located in a serine and threonine rich region of the antibody surface and is surrounded by five polar side chains (Ser24, Ser71, Ser73, Ser75, Thr78). The mutations Lysl86Gln and Lysl95Thr are both charge changes in or near the recognition surface of the antibody, and while these are not CDR residues, it is possible they may be directly involved in antigen binding. To evaluate which of the three versions of resurfaced anti-B4 may be optimal for clinical development, the Kabat database (Kabat et al., 1991) was examined to determine human residue preferences at positions 76, 186, and 195. At position 76 of V L , no human K V L sequences had a Ser at position 76, while Asp was seen in 101 out of 135 human K V L sequences. At position 186 of V H in Kabat human subgroup I (the LS5 V H is a member of subgroup I), Gin was found in 44 of 49 sequences while Lys appeared only once. However, at position 195 there was no marked preference for either the human Thr or the murine Lys in the 49 human sequences, with Thr present in 21 sequences and Lys in 11 sequences. We concluded that the surface pattern of the resurfaced version RB4v7.2 antibody was closest to the surface pattern of a human antibody.
Models of the optimal CDR-grafted and resurfaced antibodies were then compared ( Figure 5 ). Both Fv sequences contain a similar percentage of total murine framework and CDR residues, 39% for RB4v/.2 and 28% for GB4v2J. However, RB4v7.2 and GB4v2.J contain one and three murine residues at framework surface positions, respectively. While such comparisons cannot be used to predict the immunogenicity of antibodies, they do suggest that the resurfacing strategy can be used to design humanized antibodies that are no more likely to be immunogenic than a corresponding CDR-grafted version. (upper panel) and VH (lower panel) framework sequences for 12 published CDR-grafted antibodies aligned with CDR-grafted anti-B4 antibody GB4v2.5, CDR-grafted N901 GN901v/./, resurfaced anti-B4 RB4v/.2, and resurfaced N90I RN901v/./. Surface accessible residues as determined by Pedersen et al. (1994) are shaded. A reverse shaded box indicates a framework position where a murine residue was introduced in the human framework to improve binding affinity. References for published CDR-grafted sequences: I. Cot/ al. (1992) ; 2. Queen et al. (1989); 3. Carter et al. (1992) ; 4. Woodle et al. (1992) ; 5. Gorman et al. (1991); 6. Hakimi et al. (1993); 7. Shearman et al (1991) ; 8. Tempest et al. (1991); 9 Maeda et al. (1991) ; 10. Kettleborough et al. (1991) ; 11. Presta</a/. (1993); 12. Kolbinger et al. (1993) 
Discussion
The goal for the humanization by CDR grafting of murine monoclonal antibodies N901 and anti-B4 was to generate human IgGi antibodies that would retain the full binding affinity and specificity of the parent murine antibodies using a minimal number of murine amino acid residues in the Fv framework sequences to reduce the probability of an immune response in man. For both antibodies this goal was achieved by selecting the most identical human V H and V L sequences without regard to clonal origin. For N901, we paired the V L from KV2F and V H from G36005 and for anti-B4, the V L from POP and V H from 21/28. The human frameworks selected for N901 had identity to the murine sequences to such a degree (V L 84% and V H 86% ) that the goal of maintaining full affinity in the CDR-grafted antibody could be achieved by simply transferring the CDRs from the murine N901 to the human Fv framework. No further changes in the Fv framework were necessary. The successful CDR-grafting of anti-B4 required, as observed for most other published humanized antibodies (reviewed in Adair, 1992) , the substitution of critical murine residues into the human framework in order to maintain the parental binding affinity. The most identical human sequences to anti-B4 showed a 73% and 77% identity across the V L and V H sequences, respectively. Two versions of CDR-grafted anti-B4 were generated which retained the full binding affinity of the murine antibody, with GB4v2J having a total of 12 murine framework substitutions.
Humanization of murine monoclonal antibodies through variable domain resurfacing is based on the premise that the human anti-murine antibody (HAMA) response to the variable region is directed to surface residues only. This assumption has not been tested yet for immunoglobulins but is generally accepted for the immunogenicity of proteins (Tainer et al., 1984; Westhof et al, 1984; Novotny et al, 1986; Thornton et al, 1986; reviewed in Benjamin et al., 1984) . We and others (Hurle and Gross, 1994) have speculated that few framework surface residues are involved in maintaining CDR conformations or interact directly with antigen. Therefore few, if any, potentially immunogenic murine Fv surface residues will need to be retained in a resurfaced antibody to maintain the parental binding affinity. The original resurfaced versions of the N901 (RN901W.0) and anti-B4 (RB4v7.0) antibodies (Pedersen et al, 1994; Roguska et al, 1994) retained one and three murine Fv surface residues, respectively. The residues at these positions were considered, from computer models, to be candidates for CDR interactions. Experiments were performed in which the murine surface residues were systematically replaced by the human residues. The single murine surface residue in N901 could be replaced without affecting the binding affinity, thereby creating a resurfaced N901 Fv with a completely human framework surface. For anti-B4, fully humanizing the surface resulted in a lower binding affinity relative to the murine antibody. However, full binding could be restored by the reintroduction of a single murine residue. Interestingly, with respect to affinity, it was irrelevant which of the three sequence positions was occupied by a murine residue. We propose that in such instances selection should be made according to the residue preference for the human antibodies listed in the Kabat database. Of the constructions made, RB4v7.2 had a surface pattern most closely resembling that of the human antibody. These results lend support to the notion that few Fv surface residues are important for maintaining binding affinity.
In seeking further supportive evidence for this idea, we also analyzed the sequence positions of murine residues that were retained for the purpose of maintaining binding affinity in Fv sequences of published CDR-grafted antibodies. Table III lists twelve published examples of V H and V L framework sequences of CDR-grafted antibodies known to us, together with the resurfaced and CDR-grafted anti-B4 and N901 sequences. The surface residue positions and the murine amino acid residues are highlighted. While the published framework sequences of CDR-grafted antibodies contain between 0 and 22 murine residues (Table III) , five Fv sequences contain no murine residues on the surface and four sequences have only one murine surface residue. This analysis suggests again that few surface residues contribute to binding and indicates that humanization by variable domain resurfacing has a high probability of maintaining the original affinity of the murine antibody.
Variable domain resurfacing maintains the core murine residues of the Fv sequences, and it could be argued that these foreign sequences, despite being internal, could elicit an immune response. As noted above, CDR-grafted antibodies also generally contain some murine framework amino acid residues and rather few are located at surface positions. Indeed, in the framework sequences of the CDR-grafted antibodies listed in Table III , between 0 and 16 murine residues are part of the Fv core. The two resurfaced antibodies shown here, RB4v7.2 and RN901v/.7, have 36 and 22 murine core residues, respectively. While these numbers are about two-to three-fold larger than for CDR-grafted antibodies, this difference may not be significant for the human immune system (see discussion, Pedersen et al., 1994) . Furthermore, considering that eight of the 12 published CDR-grafted sequences listed in Table III did not maintain the full binding of their parent antibodies, the number of murine residues quoted for these CDR-grafted versions would be expected to increase with additional attempts at improving affinity, thereby further diminishing the differences between CDR-grafted and resurfaced antibodies.
CDR-grafted and resurfaced versions of N901 were generated (GN9Olv/.7 and RN9Olv/.7) that had no murine residues at surface framework positions. Because the CDR-grafted version contains no murine core framework residues as well, a conservative approach would be to choose this antibody over the resurfaced version for a therapeutic application. For anti-B4, however, the CDR-grafted and resurfaced versions differed in the degree to which their surfaces could be humanized with retention of full binding affinity. The best CDR-grafted version, GB4v2.5, required three murine residues at surface positions to maintain binding, while the best resurfaced versions needed only one surface murine residue. Thus, even though the resurfaced version of anti-B4 RB4v/.2 has 36 murine residues in the Fv core, it is conceivable that it would be less immunogenic than the CDR-grafted version with nine murine residues in the Fv core because it has a pattern of surface residues that is more identical to a human surface pattern. This argument ignores, of course, the possibiltiy of immunogenic Tcell epitopes, the importance of which in antibody immunogenicity is unknown. While this hypothesis can only be proven by clinical trials, this analysis would predict that similarly low immunogenicity might be expected for Fv resurfaced antibodies as has been observed for CDR-grafted antibodies (see unpublished proceedings of the Fifth Annual IBC Conference on Antibody Engineering, 7-9 December, 1994, San Diego, USA, and the unpublished proceedings of the Tenth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, 9-11 March, 1995, San Diego, USA; Anasetti et al., 1994; Caron et al., 1994) .
